Payment overview · 2025
General Payments
$533.42
25 reported records · 6 companies
Healthcare provider profile · identity verified
Lorelei Mcmillian, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · REDMOND, OR · NPI 1053387860
Verified facts
What the public records show
CMS Open Payments records show Lorelei Mcmillian, FNP received $533.42 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.42 | 34.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.24 | 30.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $91.47 | 17.1% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.82 | 10.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.12 | 4.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.35 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $501.44 | 23 |
| Education | $31.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $131.26 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $131.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $127.13 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.27 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $91.47 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.82 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 498 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 92 |
| Lisinopril | Lisinopril | 279 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 46 |
| Omeprazole | Omeprazole | 222 | 59 |
| Gabapentin | Gabapentin | 212 | 62 |
| Losartan Potassium | Losartan Potassium | 201 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 59 |
| Alprazolam | Alprazolam | 179 | 49 |
| Trazodone Hcl | Trazodone Hcl | 176 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 46 |
| Metformin Hcl | Metformin Hcl | 135 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 51 |
| Sertraline Hcl | Sertraline Hcl | 127 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 19 |
| Bupropion Xl | Bupropion Hcl | 117 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 14 |
| Buspirone Hcl | Buspirone Hcl | 104 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 32 |
| Simvastatin | Simvastatin | 100 | 27 |
| Eliquis | Apixaban | 93 | 20 |
| Tramadol Hcl | Tramadol Hcl | 91 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 25 |
| Meloxicam | Meloxicam | 87 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 13 |
| Montelukast Sodium | Montelukast Sodium | 83 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 24 |
| Furosemide | Furosemide | 82 | 24 |
| Atenolol | Atenolol | 77 | 20 |
| Ozempic | Semaglutide | 77 | 13 |
| Methocarbamol | Methocarbamol | 74 | 22 |
| Potassium Chloride | Potassium Chloride | 74 | 24 |
| Estradiol | Estradiol | 70 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 16 |
| Lorazepam | Lorazepam | 62 | 15 |
| Synthroid | Levothyroxine Sodium | 62 | 17 |
| Progesterone | Progesterone, Micronized | 60 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 17 |
| Aripiprazole | Aripiprazole | 53 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Lamotrigine | Lamotrigine | 49 | suppressed |
| Lovastatin | Lovastatin | 49 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Allopurinol | Allopurinol | 45 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Xarelto | Rivaroxaban | 44 | 11 |
| Clonazepam | Clonazepam | 41 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 14 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 13 |
| Baclofen | Baclofen | 34 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 34 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 14 |
| Carvedilol | Carvedilol | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 14 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Prednisone | Prednisone | 24 | 19 |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Spironolactone | Spironolactone | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.42 · 25 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, EVENITY, FARXIGA, GEMTESA, NURTEC ODT, PROLIA, QULIPTA, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error